Table 1.
Baseline characteristics of the patients.
| Characteristic | Training set (n = 209) | Validation set (n = 89) | P |
|---|---|---|---|
| Sex | |||
| Male | 164 (78.5) | 69 (77.5) | 0.979 |
| Female | 45 (21.5) | 20 (22.5) | |
| IC | |||
| IC0 | 59 (28.2) | 25 (28.1) | 0.757 |
| IC1 | 81 (38.8) | 31 (34.8) | |
| IC2 | 69 (33.0) | 33 (37.1) | |
| TC* | |||
| TC0 | 164 (78.8) | 74 (83.1) | 0.494 |
| TC1 | 14 (6.7) | 3 (3.4) | |
| TC2 | 30 (14.4) | 12 (13.5) | |
| TMB, mut/Mb† | |||
| Median (Interquartile range) | 8 [5, 14] | 8 [5, 14] | 0.662 |
| Treatment response | |||
| Complete response | 14 (6.7) | 11 (12.4) | 0.059 |
| Partial response | 26 (12.4) | 17 (19.1) | |
| Stable disease | 42 (20.1) | 21 (23.6) | |
| Progressive disease | 127 (60.8) | 40 (44.9) | |
| Gene score | |||
| Median (Interquartile range) | -1.490 [-1.615, -1.352] | -1.475 [-1.597, -1.286] | 0.355 |
Data are presented as No. (%) unless indicated otherwise.
P values were derived from the univariable association analyses between the training and validation set.
*One patient’s PD-L1 expression on tumor cells (TC) data was not available.
†TMB data were available for 161 and 73 patients in the training and validation sets, respectively.